David D’Alessio, chief of endocrinology and metabolism at Duke University, and Randy Seeley, a professor at the University of Michigan, delve into the groundbreaking GLP-1 drugs like Ozempic. They reveal these drugs’ potential to combat not just Type 2 diabetes and obesity, but also addictions, migraines, and even neurological diseases like Alzheimer’s. The discussion uncovers the science behind why these medications perform so many functions and considers the implications of making them more widely available for general health.
